Haemonetics sells whole blood assets to GVS, likely boosting stock

From Nasdaq: 2025-01-20 08:01:00

Haemonetics completes the sale of its whole blood assets to GVS, S.p.A, for up to $67.8 million. The move aims to enhance its leadership in plasma and hospital markets. Despite a recent 8.1% drop in stock price, the company’s earnings yield of 6.25% and positive industry outlook suggest potential growth for HAE shares.

The sale to GVS aligns with Haemonetics’ strategy to focus on apheresis solutions while supporting existing whole blood customers. The company plans to utilize proceeds for growth initiatives and general corporate purposes, with details on fiscal year 2025 impact expected during the third-quarter earnings call. The apheresis market is projected to grow at an 8.3% CAGR through 2031.

In related news, Haemonetics recently announced the availability of its VASCADE MVP XL system in the U.S. market. Despite a stock decline of 18.6% in the past six months, the company carries a Zacks Rank #2 (Buy). Other top-ranked medical stocks include Phibro Animal Health, Penumbra, and Abbott Laboratories, each showing strong earnings growth potential and positive market performance.

For investors seeking high-growth opportunities, Zacks Investment Research highlights five potential stock picks set to double in 2024. These under-the-radar stocks offer significant growth potential and opportunities for investors looking to capitalize on emerging trends in the medical sector. Visit Zacks for more details on these promising investment prospects.



Read more at Nasdaq: Completion of Whole Blood Assets Sale to GVS Likely to Boost HAE Stock